DJIA 16,643.01 -11.76 -0.07%
NASDAQ 4,828.33 15.62 0.32%
S&P 500 1,988.87 1.21 0.06%
market minute promo

Biogen Idec (NASDAQ: BIIB)

303.69 -0.80 (-0.26%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

BIIB $303.69 -0.26%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $301.00
Previous Close $304.49
Daily Range $299.76 - $306.45
52-Week Range $265.00 - $480.18
Market Cap $71.4B
P/E Ratio 20.56
Dividend (Yield) $0.00 (0.0%)
Volume 2,059,085
Average Daily Volume 3,407,115
Current FY EPS $15.92




Drug Makers

Biogen Idec (BIIB) Description

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies. Website:

News & Commentary Rss Feed

We Believe Healthcare's Next Biotech Buyout Target Is…

Which biotech company will be the next buyout target? To answer this question, we turned to three of our healthcare contributors, and this is what they had to say.

Get Ready For The Second Round Of The Market Downturn

Cramer Remains Cautious on Stocks

Biogen And Gilead Sciences Catch The Eye Of Short Sellers

IVW, NKE, BIIB, KMI: Large Outflows Detected at ETF

2 Reasons I'm Bullish for Biogen's Future

Two potential mega-blockbuster opportunities make this the biotech stock to watch.

Comments On The Market Correction; Focus On Biotechs: Large Caps

Drugs Stocks On The Rise With Help From 3 Stocks

Biotech Stock Roundup: Acorda Gains on Patent Issues, Vital Crushed by Liver Data

Short Sellers Become More Focused in Major Biotechs

See More BIIB News...

BIIB's Top Competitors

BIIB $303.69 (-0.26%)
Current stock: BIIB
AMGN $155.89 (0.11%)
Current stock: AMGN
GILD $107.78 (-0.19%)
Current stock: GILD
$0.00 (0.00%)
Current stock: